©The Author(s) 2019.
World J Clin Cases. Jun 26, 2019; 7(12): 1367-1382
Published online Jun 26, 2019. doi: 10.12998/wjcc.v7.i12.1367
Published online Jun 26, 2019. doi: 10.12998/wjcc.v7.i12.1367
Table 1 International guidelines for hepatocellular carcinoma surveillance programs
| Guideline | Indications | AFP | Imaging | Period (mo) |
| WHO | HBV DNA > 2000 UI/mL, HCV cirrhosis | + | US | 6 |
| Canadian | Cirrhosis, HBV chronic carriers | US | 6 | |
| AASLD | Cirrhosis | +/- | US | 6 |
| NCCN | Cirrhosis, HBV chronic hepatitis | +/- | US | 6 |
| Australian | US | |||
| EASL | US | 6 | ||
| Japan | Cirrhosis | + | US/dynamic CT/MRI | 3-6 |
| Asia-Pacific | > 200 ng/mL | US | 6 |
- Citation: Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382
- URL: https://www.wjgnet.com/2307-8960/full/v7/i12/1367.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i12.1367